# Epidemiological and Clinical Features of Mpox during the Clade Ib Outbreak in South-Kivu, Democratic Republic of the Congo: a Prospective Cohort Study

# Authors

Isabel Brosius<sup>1#</sup>, Emmanuel Hasivirwe Vakaniaki<sup>1,2#</sup>, Guy Mukari<sup>3</sup>, Papy Munganga<sup>4</sup>, Jean Claude Tshomba<sup>5</sup>, Elise De Vos<sup>1</sup>, Eugene Bangwen<sup>1,6</sup>, Yves Mujula<sup>2</sup>, Achilleas Tsoumanis<sup>1</sup>, Christophe Van Dijck<sup>1</sup>, Aimé Alengo Odud<sup>7</sup>, Léandre Mutimbwa-Mambo<sup>8</sup>, Franklin Mweshi Kumbana<sup>9</sup>, Jenestin Babingwa Muunga<sup>9</sup>, Divin Mazambi Mambo<sup>9</sup>, Jems Wakilongo Zangilwa<sup>9</sup>, Steeven Bilembo Kitwanda<sup>9</sup>, Sarah Houben<sup>1</sup>, Nicole A. Hoff<sup>10</sup>, , Jean-Claude Makangara-Cigolo<sup>2,11</sup>, Eddy Kinganda-Lusamaki<sup>2,12</sup>, Martine Peeters<sup>12</sup>, Anne W. Rimoin<sup>10</sup>, Jason Kindrachuk<sup>13</sup>, Nicola Low<sup>11</sup>, Patrick DMC. Katoto<sup>14,15</sup>, Espoir Bwenge Malembaka<sup>14,16</sup>, John H. Amuasi<sup>17,18</sup>, Olivier Tshiani-Mbaya<sup>2</sup>, Dally Muamba Kambaji<sup>19</sup>, Richard Kojan<sup>19</sup>, Cris Kacita<sup>20</sup>, Daniel Mukadi-Bamuleka<sup>2,5,21</sup>, Steve Ahuka-Mundeke<sup>2,21</sup>, Koen Vercauteren<sup>1</sup>, Tony Wawina-Bokalanga<sup>1,2,21</sup>, Jean-Jacques Muyembe-Tamfum<sup>2,21</sup>, Sabin Sabiti Nundu<sup>1,2</sup>\*, Laurens Liesenborghs<sup>1,6\*§</sup>, Placide Mbala-Kingebeni<sup>2,21\*§</sup>

# Contributed equally
\* Supervised jointly and contributed equally

*\$ Corresponding authors:* 

Laurens Liesenborghs, MD, PhD, Institute of Tropicale Medecine, Nationalestraat 155, 2000 Antwerp, Belgium; email: lliesenborghs@itg.be

Placide Mbala Kingebeni, MD, PhD, Institut National de Recherche Biomédicale (INRB), Av. De la Démocratie N°5345, Kinshasa – Gombe, Democratic Republic of the Congo; email: placide.mbala@inrb.cd

# Author affiliations

<sup>1</sup> Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

<sup>2</sup> Institut National de Recherche Biomédicale (INRB), Democratic Republic of the Congo

<sup>3</sup> National Program for HIV/AIDS, Ministry of Public Health, Kinshasa, Democratic Republic of the Congo

<sup>4</sup>National Police Hospital, Goma, Democratic Republic of the Congo

It is made available under a CC-BY-NC-ND 4.0 International license .

<sup>5</sup> Rodolphe Mérieux Institut National de Recherche Biomédicale, Goma Laboratory, Goma, Democratic Republic of the Congo

<sup>6</sup> Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

<sup>7</sup> Division Provinciale de la Santé, South Kivu, DRC

<sup>8</sup> Kamituga Health Zone, South Kivu, DRC

<sup>9</sup> Kamituga General Hospital, South Kivu, DRC

<sup>10</sup> Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, California, USA

<sup>11</sup> Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

<sup>12</sup> TransVIHMI (Recherches Translationnelles sur le VIH et les Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement (IRD), Institut National de Santé et de Recherche Médicale (INSERM), Montpellier, France

<sup>13</sup>University of Manitoba, Winnipeg, Manitoba, Canada

<sup>14</sup>Center for Tropical Diseases and Global Health, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo

<sup>15</sup> Cochrane South Africa, Medical Research Council of South Africa, Division of Epidemiology and Biostatics, Department of Global Health, Faculty of Medicine, Stellenbosch University, South Africa

<sup>16</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.

<sup>17</sup> Global Health and Infectious Diseases Research Group, Kumasi Center for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

<sup>18</sup> Research Group Global One Health, Department of Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

<sup>19</sup> The Alliance for International Medical Action, Goma, Democratic Republic of the Congo

<sup>20</sup> National Program for Monkeypox and Viral Hemorrhagic Fevers, Ministry of Health, Kinshasa, Democratic Republic of the Congo

<sup>21</sup> Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo

It is made available under a CC-BY-NC-ND 4.0 International license .

# 1 **ABSTRACT**

### 2 BACKGROUND

Clade Ib, a new strain of the Clade I monkeypox virus, emerged in Eastern Democratic
Republic of the Congo, sparking an international outbreak. Comprehensive studies are
needed to assess its transmission dynamics and clinical presentation.

# 6 METHODS

7 We conducted a prospective observational cohort study at Kamituga General Hospital in 8 South Kivu, DRC, between May 2 and October 9, 2024. Sociodemographic, exposure and 9 clinical data were collected from mpox suspected cases. Cases confirmed by Xpert<sup>®</sup> Mpox 10 PCR were presumed Clade Ib infections (awaiting Clade confirmation) and followed through 11 hospitalization and on days 29 and 59 post-diagnosis to assess clinical progression and 12 outcomes.

#### 13 **FINDINGS**

14 Of 511 included suspected cases, 431 (84%) tested PCR positive; with 205 being women 15 (47%). Age distribution was bimodal, with 279 (65%) individuals aged 15-34 years, and 63 16 (15%) children under five. Most cases (59%) reported contact with a suspected or confirmed 17 mpox case; among adults, this was primarily a spouse, colleague or sexual partner, while for 18 children, the primary contacts were parents or siblings. Comorbidities were rare (4%), 19 including six (1%) HIV infections. Prodromal symptoms were present in 346 (88%) patients, 20 active skin lesions in 414 (96%), mucosal lesions in 338 (82%), and lymphadenopathy in 295 21 (71%). In adults, lesions were more concentrated in the genital area, with 90% of adults 22 presenting lesions in this region. In contrast, only 39% of children had genital lesions, with 23 lesions more frequently found elsewhere on the body. Among 427 hospitalized patients, 24 two deaths (0.5%) occurred. Among 315 patients with detailed hospital follow-up, 25 complications were primarily genito-urinary (55%) or cutaneous (40%). Four of six pregnant 26 women with recorded outcome (67%) had adverse pregnancy outcomes. Significant 27 sequelae at days 29 and 59 were rare.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 28 INTERPRETATION

- 29 Clade Ib MPXV infections presented differently from previously reported Clade Ia and Clade
- 30 IIb infections. In adults, the disease primarily affected the genito-urinary system, compatible
- 31 with sexual transmission, while children mostly manifested extragenital lesions.

# 32 FUNDING

- 33 European & Developing Countries Clinical Trials Partnership (EDCTP2 and EDCTP3); Belgian
- 34 Directorate-General Development Cooperation and Humanitarian Aid; Research Foundation
- 35 Flanders

It is made available under a CC-BY-NC-ND 4.0 International license .

### 37 INTRODUCTION

38 Mpox is a disease caused by monkeypox virus (MPXV). Until recently, human mpox was 39 considered an endemic zoonosis, linked to contact with wildlife infected with MPXV Clade I 40 in Central Africa or MPXV Clade II in West Africa.<sup>1</sup> However, in recent years, two distinct 41 lineages of MPXV capable of sustained human-to-human transmission have emerged, 42 leading to major international outbreaks.<sup>2</sup>

In 2017, a subclade of Clade II, named Clade IIb began to circulate in Nigeria through human-to-human transmission, including through sexual contact.<sup>3</sup> The subsequent international spread of Clade IIb culminated in the 2022 global outbreak, with over 100,000 documented mpox cases to date. The outbreak overwhelmingly affected adult men – often identifying as men-who-have-sex-with-men (MSM) – , who predominantly presented with relatively mild disease and predominantly anogenital or oral lesions.<sup>1,4</sup> The overall case fatality rate (CFR) was below 0.1%.<sup>2</sup>

A similar scenario is currently unfolding with Clade I in the Democratic Republic of the Congo (DRC). The country notified a substantial increase in Clade I MPXV infections over multiple decades, primarily in remote rural areas, where outbreaks are largely due to zoonotic spillover and predominantly impact children.<sup>5,6</sup> Historically, Clade I infections have been associated with a generalized papulopustular rash, with potentially severe outcomes and a reported CFR of 2·9% among suspect cases.<sup>5,7,8</sup>

In September 2023, however, a new lineage of Clade I MPXV emerged in a densely 56 populated urban and previously unaffected region in South Kivu, DRC. <sup>9–11</sup> Phylogenomically, 57 the lineage constitutes a distinct cluster, named Clade Ib, distinct from other Clade I 58 lineages that are now denoted Clade Ia.<sup>10</sup> The subsequent rapid human-to-human spread of 59 60 Clade Ib in South Kivu resulted in the notification of 2,672 confirmed mpox cases between January 1 and October 20, 2024. Of these, 157 samples were sequenced, with 156 showing 61 62 Clade Ib.<sup>12,13</sup> From South Kivu, Clade Ib spread to other provinces within the country and cross-border to neighboring countries. Consequently, in August 2024, both the Africa Center 63 64 for Disease Control (CDC) and the World Health Organization (WHO) issued emergency declarations.<sup>14</sup> 65

It is made available under a CC-BY-NC-ND 4.0 International license .

Unlike Clade Ia, early reports about Clade Ib mpox suggested that mainly adolescents and
young adults were affected, with lower disease severity and predominantly genital
lesions.<sup>10,11,13</sup> Clade Ib, therefore, exhibits notable similarities with Clade IIb mpox. However,
robust clinical data are lacking.

70 Large prospective studies are needed to characterize the ongoing Clade Ib mpox outbreak,

71 given apparent changes in affected populations, clinical presentation, disease outcome, and

72 transmission dynamics. This manuscript describes the epidemiological and clinical

characteristics of the Clade Ib mpox outbreak in South Kivu, DRC.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 74 MATERIAL AND METHODS

### 75 STUDY DESIGN, SITE AND PARTICIPANTS

The Mpox Biology, Outcome, Transmission, and Epidemiology - Kamituga (MBOTE -76 77 Kamituga) study is a prospective observational cohort study of Clade Ib MPXV-infected 78 individuals (clinicaltrials.gov: NCT06652646). Participants were enrolled at Kamituga 79 General Hospital (KGH), which hosts a large mpox treatment center for Kamituga and 80 surrounding health zones. Kamituga Health Zone, the initial epicenter of the Clade Ib mpox 81 outbreak, is an urbanized region in South-Kivu province, eastern DRC, with a population estimated at 242,000 people.<sup>15</sup> On-site diagnostic testing capacity for mpox was installed, 82 and a new isolation unit was set up with an admission capacity of 37 beds. 83

All individuals suspected of having mpox who presented to the hospital for diagnostic testing and care, and who provided written informed consent were included in the study. Participants were enrolled prior to diagnostic testing and underwent a baseline investigation. Only individuals who tested positive via Mpox Xpert® PCR were subsequently followed up longitudinally.

# 89 PROCEDURES AND DATA COLLECTION

90 A baseline standardized case report form (CRF), programmed into a REDCap<sup>™</sup> database 91 (Vanderbilt University, Nashville, TN), was completed by a study physician. The CRF 92 captured data on exposure, behaviors, socio-demographic profile, medical history including 93 HIV and smallpox vaccination status, as well as presence and onset date of symptoms. 94 Questions about sexual behaviors were restricted to people over 12 years old. Physical 95 examination findings at enrolment included lesion count, lymphadenopathy, and presence 96 or absence of complications.

97 Skin lesions and oropharyngeal swabs were taken for on-site diagnostic testing with Xpert<sup>®</sup> 98 Mpox cartridges on the 4-module GeneXpert system (Cepheid, Sunnyvale, California CA, 99 USA). This automated real-time PCR detects non-variola Orthopoxvirus (OPXV) and MPXV 100 Clade II DNA .<sup>16</sup> A sample was considered positive for MPXV Clade I, if non-variola OPXV 101 DNA was detected with a cycle threshold value below 39 and MPXV Clade II PCR was

It is made available under a CC-BY-NC-ND 4.0 International license .

negative, following guidelines from the DRC laboratory working group led by WHO. At thetime of preprint publication, Clade Ib confirmation is ongoing.

104 Individuals with a positive lesion or oropharyngeal sample were admitted to KGH for 105 isolation and medical care and followed-up by the study team. The evolution of symptoms, 106 signs, and complications was documented in a CRF. Patients received supportive care, 107 consisting of symptomatic therapy (analgesia, antipyretics), nutritional support, skin care, 108 correction of hypovolemia, antibacterial and antimalarial treatment where indicated. No 109 MPXV-specific antivirals were available. Malaria and HIV rapid diagnostic tests, hemoglobin assays, point-of-care glucometry, and HCG dipstick tests were performed at the discretion 110 111 of the treating physician. Testing for other sexually transmitted infections, Varicella, 112 bacterial infections, and biochemical analyses were not available. Patients were discharged 113 at the discretion of the treating physician team.

After discharge, participants were invited for follow-up visits on days 29 and 59 post- mpox diagnosis to record data on residual or new signs and symptoms. Pregnant women were advised to return to KGH for any pregnancy-related complications, or at the start of labor. Pregnancy related outcomes were captured in a dedicated CRF.

### 118 STATISTICAL ANALYSIS

119 Demographic, clinical and behavioral characteristics were described using medians and 120 interguartile ranges (IQR) for continuous variables and counts and percentages for 121 categorical variables. For the representation of the clinical data, participants were 122 categorized into three age groups based on expected physiological and exposure 123 differences: children under five years, children aged five to 14 years, and individuals aged 15 124 years and older. The latter group will be referred to as adults throughout the manuscript. 125 The association between sociodemographic and exposure characteristics and MPXV-PCR 126 test results among mpox suspected cases was tested using Fisher exact test for categorical 127 characteristics and Mann-Whitney non-parametric test for continuous variables. The 128 resulting p-values were corrected for multiple testing using the Benjamini-Hochberg 129 method. The time from symptom and lesion onset to resolution were calculated and the 130 results were presented using survival Kaplan-Meier curves. Data were analyzed using R 131 statistical software, version 4.3.1.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 132 ETHICAL CONSIDERATIONS

The study was approved by the Ethics Committee of the University of Kinshasa (approval ID ESP/CE/78/2024) and the Ethics Committee of the University Hospital Antwerp (ID 6383). Written consent was obtained prior to all study procedures from participants aged 18 years and older, and from parents or guardians for minors. Children from 12 to 17 years old received age-appropriate information and signed an assent form. Pictures for publication were taken with additional written consent. All participants received reimbursement of transportation costs for visits and free care and nutrition.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 140 **RESULTS**

141 Between May 2 and October 9, 2024, 511 people with suspected mpox were enrolled in the

study (Supplementary figure 1) of which 431 (84%) tested positive on Xpert<sup>®</sup> PCR.

### 143 **DEMOGRAPHICS, EXPOSURE AND RISK FACTORS**

Of all 431 confirmed cases, 205 (47.6%) were women (Table 1). The median age was 22 (IQR 145 17-29, range 1 week to 79 years). Individuals aged 15-34 accounted for 65% of all infections, 146 while children aged 10-14, 5-9, and under five years represented 3%, 4%, and 15%, 147 respectively. (Figure 1A) The most reported occupations were mine worker (100, 24%) and 148 sex worker (53, 13%).

149 Among confirmed cases, 59% (n=253) reported contact with one or more suspected or 150 confirmed mpox cases in the three weeks before diagnosis. Among the 57 children with this 151 exposure, potential infectors were primarily household members (n=75, 83%). These 152 household contacts were predominantly parents (47%) or siblings (53%). Similarly, the 197 153 adults with known contact, most frequently reported household members (n=91, 37%) as 154 potential infectors, with spouses being the most common household contact (56/91, 62%). 155 Other frequently mentioned potential infectors among adults were colleagues (n=81, 33%) 156 and sexual partners outside the household (n=50, 21%). The most common exposure types 157 were skin-to-skin contact (n=246, 97%), prolonged conversation (>15 min) (n=243, 96%), 158 shared meals or utensils (n=227, 90%), and shared bedding (n=176, 70%), with 42% (n=107) 159 reporting sexual exposure.

Of the 348 confirmed mpox patients aged 12 years or older questioned on sexual behavior, 293 (84%) reported having sex in the previous three weeks. Among these, 127 (43%) reported having more than one sexual partner and 135 (42%) having engaged in transactional sex. Only 16% (n=59) of confirmed cases reported contact with wild animals through hunting, handling, or consumption.

165 Comparing people with suspected mpox who tested positive with those who tested 166 negative, we observed an older age distribution (median age 22 vs 17, p=0.034), and a 167 higher proportion of sex workers (although statistically not significant, 13% vs 5%, p=0.117) 168 and mine workers (24% vs 8%, p=0.005) among the confirmed cases. Compared with non-

It is made available under a CC-BY-NC-ND 4.0 International license .

infected individuals, confirmed cases more often reported having sexual intercourse (84% vs 57%, p=0.001), including transactional sex (42% vs 16%, p=0.003), and more often reported contact with another mpox case in the three weeks preceding their diagnosis. (59% vs 41%, p=0.015).

#### 173 MEDICAL HISTORY AND CLINICAL PRESENTATION AT ADMISSION

Only 18 (4%) mpox patients reported comorbidities, including malnutrition (n=10), HIV (n=6), tuberculosis (n=1) and chronic liver disease (n=1). (Table 2) Seven (2%) MPXV-infected participants reported smallpox vaccination during childhood. Twenty-one infected women (10%) were pregnant at the time of inclusion.

178 Mpox-confirmed patients presented at the study site a median of seven (IQR 5 - 10) days 179 after the onset of symptoms and five (IQR 4-7) days after the appearance of skin lesions 180 (Table 2). Prodromal symptoms preceded the rash in 346 (88%) of patients. Systemic 181 symptoms such as fatigue, malaise and myalgia were highly prevalent, affecting 384 (90%), 182 320 (75%) and 301 (71%) of patients, respectively. The lesions commonly caused itching 183 (92%) or pain (78%). Eye pain and visual problems were reported in 20% and 10% of cases 184 respectively, mostly among adults. Adult mpox patients often had genital pain (n=116, 53%), 185 dysuria (n=166, 50%), or rectal pain (n=45, 14%). Anogenital symptoms rarely occurred 186 among children.

At inclusion, 21 (5%) of mpox cases had a temperature above 38°C (Table 2). Active skin lesions were present in 414 (96%) patients. The median total lesion count at admission was 42 (IQR 17-94, range 1-1420). Most participants (n=326, 79%) had a combination of different lesion types, including vesicles (n=291, 70%), papules (n= 222, 54%) and small pustules (n=178, 43%). Umbilicated pustules were observed in 156 participants (38%), ulcers in 94 (23%) and macules in 62 (15%). Children up to 14 years old, however, mostly presented with papules (n=66, 73%) and umbilicated pustules were rare (n=14, 16%).

One third (n=141, 34%) of patients had generalized rash, defined as lesions on at least eight out of ten body regions (Table 2). Less than half of patients had lesions on the palms of the hands (n=167, 42%) or on the soles of the feet (n=100, 20%). Adults more often had genital skin lesions than children (90% vs 41%, p<0.001). (Figure 1B, Table 2) The genital area made

It is made available under a CC-BY-NC-ND 4.0 International license .

up > 50% of total lesion count in 27% of adults and was the only localization of lesions in
11% of adults (vs 2 and 1%, respectively, in children). Among adults, the genital area had the
highest lesion density, while in children, lesions were more concentrated on the abdomen,
thorax, arms, and genital area (Figure 1C).

202 Complex lesions, defined as large (> 2cm in diameter), confluent or necrotic lesions were 203 present in 98 (24%) mostly adult patients (n=94), of whom 93 (95%) reported these lesions 204 in the genital region (Table 2). Mucosal lesions (n=338, 82% for any mucosal lesion) were 205 common across age groups, although genital mucosal lesions were more prevalent in adults 206 compared to children up to 14 years old (82% vs 33%, p<0.001). Lymphadenopathy differed 207 significantly over age groups (p<0.001). While common in adults (n=264, 82%) and children 208 aged 5-14 years (n=22, 69%), lymphadenopathy was less frequent in children under five 209 years old (n=9, 16%). In adults, the inguinal nodes were primarily affected, whereas in 210 children, the submandibular nodes were more commonly involved.

211

#### **OUTCOME AND COMPLICATIONS DURING HOSPITALIZATION**

Of the 431 MPXV-infected participants, all but four confirmed participants (99%) accepted to be hospitalized, of which 17 discharged themselves against medical advice. Two children under five years old died during hospitalization, giving an in-hospital mortality 0.5% (95% CI [0.1%, 1.7%]).

216 Detailed longitudinal follow-up data were available for 315 (73%) hospitalized patients. 217 (Table 3) Among those, the median duration of hospitalization was six (IQR 5-9) days. The 218 total lesion count increased during hospitalization in 148 (34.3%) participants. The median 219 maximum lesion count was 59 (IQR 23-139, range 1-1420) and occurred a median of 7 days 220 (IQR 5-9) after the onset of lesions. Based on maximum lesion count and according to the 221 WHO clinical severity score, 78 (25%) patients had mild disease (<25 lesions), 127 (41%) had 222 moderate disease (25-99 lesions), 60 (19%) had severe disease (100-249 lesions) and 47 223 (15%) had grave disease. The median time from onset to resolution of lesions was 14 (95% 224 Cl 14-16) days, and of symptoms overall was 18 (95% Cl 17-19) days. (Figure 1E and F)

Overall, 200 (64%) of the 315 hospitalized patients experienced complications during observation, including genital oedema or urethritis (n=121, 38%, each), complex mucosal

It is made available under a CC-BY-NC-ND 4.0 International license .

lesions (n=120, 38%), complex skin lesions (n=102, 32%), secondary bacterial infections
(n=57, 18%) or abscess formation (n=21, 7%) (Table 3). Other complications were rare (<</li>
10%).

# 230 PERSISTENT SYMPTOMS AT FOLLOW-UP

In total, 208 cases (43%) returned for assessment on day 29 and 103 cases (24%) on day 59.
(Table 4) At follow-up on day 29, 2 (1%), participants reported a decline in general health
compared to before the onset of mpox. No one reported a decline in general health on day
59.

A total of 78 (38%) participants experienced residual symptoms on day 29, and 38 (37%) on day 59. Skin-related symptoms were the most common, affecting 40 (19%) participants on day 29 and 15 (15%) on day 59. Eye symptoms were reported by 22 (11%) participants on day 29 and 18 (18%) on day 59. Five participants described reduced visual acuity on day 29 (2%) and day 59 (5%), and one person reported blindness on day 59 (1%). Other symptoms occurred in < 10% of participants on days 29 and 59. (Table 4)

On day 29, 153 (74%) participants had scars and five (2%) had active skin lesions in the form of ulcers. However, upon follow-up at day 59, only 51 (50%) still had discernible scars (Figure 1D), and one (1%) participant still had an unresolved genital ulcer. Residual mucosal lesions were noted in six (3%) participants on day 29 and one participant (1%) on day 59. (Table 4)

# 246 **PREGNANCY OUTCOMES**

247 Among the 21 pregnant women in the cohort, no adverse pregnancy outcomes occurred 248 during hospitalization. Following the initial admission, the final pregnancy outcomes were 249 recorded for six participants, where 4/6 (67%) experienced an adverse pregnancy outcome. 250 Two women suffered spontaneous abortions, during first trimester and second trimester, 251 respectively. Additionally, two women showed evidence of vertical transmission of MPXV to 252 their neonates. One fetus died in utero near the end of the second trimester, requiring 253 induction of labor. Mpox skin lesions were discernible on the head upon delivery. The other 254 child was born full term via Caesarean section due to prolonged labor complicated by 255 uterine rupture. This infant also presented with characteristic mpox skin lesions, suffered

It is made available under a CC-BY-NC-ND 4.0 International license .

- 256 from asphyxia, and died shortly after birth. The remaining two women delivered healthy
- 257 full-term babies.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 258 **Discussion**

259 This study provides a prospective, detailed characterization of patient profiles in the 260 emerging Clade Ib outbreak. Reflecting the evolving transmission pattern of Clade Ib, mpox 261 predominantly affected adolescents and young adults, though not exclusively. Exposure 262 data indicate that sexual contact is a significant driver of transmission within this group, as 263 corroborated by the prevalent genital presentations among adults. Most patients 264 experience mild to moderate disease, with complications that are primarily genito-urinary in 265 nature, and clinically significant sequelae other than scars are rare. Approximately one-fifth 266 of cases, however, were children, who typically present with more extragenital disease.

This study was conducted in a remote area of Eastern DRC, where access to high-quality healthcare is limited. However, through collaboration with the health authorities, and humanitarian organizations, we enhanced the treatment facilities and level of care provided to mpox patients. This enabled the study to be conducted within an ethically sound framework and created a suitable environment for high-quality data collection.

272 Nevertheless, working in resource-limited settings comes with inherent limitations. Firstly, 273 while the on-site diagnostic platform allowed for the detection of OPXV DNA, point-of-care 274 Clade-specific confirmation is currently unavailable. Given that Kamituga is situated at the 275 original epicenter of the Clade Ib outbreak and has no history of Clade Ia outbreaks, it is 276 highly probable that all study participants are infected with Clade Ib. At the time of this 277 preprint's publication, Clade confirmation is underway for a subset of participants. Secondly, 278 despite implementing a broad testing strategy, recruitment relied on passive case detection, 279 and the PCR positivity rate remained consistently high throughout the study (around 80%). 280 This suggests that a significant proportion of cases in the community may have gone 281 undetected. If these undetected cases involve individuals with atypical presentations, very 282 mild symptoms, or severe illness (including community deaths), their absence from the 283 study could introduce bias into the results. Additionally, the study had a large sample size, 284 but there was substantial loss to follow-up in the consecutive visits, which could impact the 285 representativeness of the data for the long-term outcomes. Finally, resource limitations 286 restricted our ability to perform additional diagnostic testing, including for HIV, other

It is made available under a CC-BY-NC-ND 4.0 International license .

sexually transmitted infections, Varicella, hematological and biochemical analyses, as well as
assessments for complications like bacterial superinfections and sepsis.

289 Despite these limitations, our findings allow for a comprehensive comparison between this 290 Clade Ib outbreak and other mpox outbreaks. While Clade Ia outbreaks in endemic regions in the DRC are typically driven by zoonotic spillover,<sup>6</sup> exposure to wild animals - and thus a 291 potential animal reservoir - was rare in our cohort. In contrast, 59% of patients recalled 292 293 contact with an index case, of which 42% included sexual contact. Additionally, the 294 overrepresentation of occupations such as sex workers and mine workers (who make up 295 most of their clientele) and the higher levels of sexual activity and more frequent 296 transactional sex among PCR-positive mpox cases compared to PCR-negative suspects, point 297 toward sexual contact as one of the drivers of transmission, similar to patterns observed in Clade IIb.<sup>4</sup> However, in contrast to the global Clade IIb outbreak,<sup>4</sup> the equal gender 298 299 distribution among mpox cases in our study suggests that transmission predominantly 300 occurred through heterosexual contact rather than male-to-male sexual contact. However, 301 because of cultural sensitivities, we did not collect information on the gender of sexual 302 partners.

303 Similar to Clade IIb infections, distinct anogenital manifestations were observed in adults with Clade Ib mpox.<sup>1,4,17</sup> Up to one-third of adults presented with predominantly genital 304 305 lesions, and over three-quarters exhibited involvement of the genital mucosa and/or 306 inguinal lymphadenopathy. In contrast, most previous Clade Ia studies reported genital 307 lesions in less than 30% of cases, typically showing a more generalized lesion distribution.<sup>8,18-20</sup> These findings suggest that the mode of MPXV transmission might 308 309 determine disease presentation. Interestingly, despite similarities in disease presentation 310 between Clades Ib and IIb, Clade Ib infections in adults appear to be somewhat more 311 severe. While only 12% of Clade IIb patients had over 20 lesions and 0-4% had more than 100, in our cohort, 66% had more than 25 lesions, and 24% exceeded 100 lesions.<sup>1</sup> This 312 313 could be caused by differences in the affected populations or in virulence between clades.

Conversely, children under 15 years exhibited a more typical clinical presentation featuring widespread lesions in a centrifugal distribution, though with a low frequency of lesions on the palms and soles.<sup>18–22</sup> In contrast to Clade Ia outbreaks, where they typically make up

It is made available under a CC-BY-NC-ND 4.0 International license .

three-quarters of cases, <sup>5, 8, 20</sup> children represented only a minority of cases in our study. 317 318 Transmission dynamics in children remain unclear; however, our data suggest that they 319 were primarily infected within the household. Household transmission was rarely reported 320 during the global Clade IIb outbreak, although in a Nigerian cohort up to 16% were children under 18 years old.<sup>23</sup> Moreover, in other health zones in South Kivu affected by the Clade Ib 321 322 outbreak and parts of neighboring Burundi, children constitute the majority of confirmed mpox cases.<sup>2,24</sup> Since our study was limited to a single health zone, caution is advised in 323 324 generalizing these findings. Further studies on transmission dynamics are essential.

325 A final important point of comparison with previously documented outbreaks are the 326 outcomes and complications of mpox. Long-term follow-up revealed few severe sequelae 327 other than scars among Clade Ib infected individuals, although one patient suffered from 328 blindness.<sup>18,19</sup> Of particular concern though, are adverse pregnancy outcomes; in our study, 329 four out of six women with recorded pregnancy outcomes lost their child, consistent with findings from Clade Ia.<sup>7,25</sup> In Clade IIb, no cases of presumed or confirmed vertical 330 transmission have been reported.<sup>26</sup> To better understand the impact of MPXV infection on 331 332 fetal development and perinatal morbidity and mortality, larger prospective cohorts of 333 pregnant women are essential.

In-hospital mortality in our cohort was low at 0.5%, with all deaths recorded in children under five. This mortality rate is higher than the 0.2% observed during the global Clade IIb outbreak in 2022—though rates as high as 6% have been reported in Nigeria<sup>23</sup> — but lower than the 1.4% to 17% reported for Clade Ia.<sup>7,10,18,19,27,28</sup> Factors such as viral virulence, transmission mode, reporting bias, population age structure, underlying comorbidities, and healthcare access may all contribute to these observed differences in mortality.

This study provides a comprehensive overview of the Clade Ib outbreak in South Kivu, highlighting shifts in transmission dynamics, clinical presentation, and patient outcomes that differ from previous Clade I and II outbreaks. Future public health interventions – such as enhanced surveillance, integrated patient management, infection control policies, contact tracing and other targeted active case detection strategies – should reflect these evolving patterns of mpox presentation. Our findings will also guide and help prioritize further research initiatives.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 347 **ACKNOWLEDGMENTS**

348 We thank all patients who agreed to be included in this cohort and particularly those who 349 provided additional consent for publication of their deidentified images. We acknowledge 350 the dedicated staff of KGH and ALIMA for their continuing expert patient care. We also 351 acknowledge the support of the Health Zone and the Provincial Health Department to 352 facilitate setting up of the study and the KGH for generously disposing the study team of 353 necessary infrastructure to pursue study activities. Finally, we thank our colleagues Inge Van 354 Cauwenberg, Marie Stéphanie Smet, Lydia Lunda, Alliance Mbandu, and Plamedi Fatouma 355 from ITM Kinshasa office administrative and logistical support.

# 356 **Funding**

357 This work was funded by the Belgian Directorate-General Development Cooperation and 358 Humanitarian Aid and the European & Developing Countries Clinical Trials 359 Partnership EDCTP3 (grant number 101195465). Additional support was provided by the Research Foundation – Flanders (FWO, grant number G096222N to EBo, LL, JJM and 360 361 12B1M24N to CVD) and through the African coaLition for Epidemic Research, Response and 362 Training (ALERRT) network. ALERRT is part of the EDCTP2 Programme supported by the 363 European Union under grant agreement RIA2016E-1612. ALERRT is also supported by the 364 United Kingdom National Institute for Health Research. EBa, EDV, and IB are members of 365 the Institute of Tropical Medicine's Outbreak Research Team, financially supported by the 366 Department of Economy, Science, and Innovation of the Flemish government (EWI). The 367 funders had no role in the conceptualization of the study, data acquisition or interpretation, 368 writing of the manuscript, or publication of the findings.

# 369 **CONFLICT OF INTEREST STATEMENT**

LL has consulted for BioNtech and received research funding from Sanofi, both not relevantfor this work. All other authors declare no conflict of interest.

### **AUTHOR CONTRIBUTIONS**

373 Conceptualized the study and wrote the protocol: IB, EHV, EDV, EB, YM, SSN, LL, PMK.

374 Participant inclusion, investigation and data collection: GM, PM, JCT, LMM, FMK. Conducted

data analysis: IB, EHV, EDV, AT, CVD, SSN, LL. Data management: SH, YM. Secured funding:

376 PKM, LL, JJMT, DM, EBM, PK, NL, AR, JA. Supervision study proceedings: LMM, FMK, CK, DM,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 377 SA, JJMT, SSn, LL, PMK. Supervised laboratory procedures: JCT, EKL, JCMC, TW, KV, DM, SA.
- 378 Writing of the initial manuscript: IB, EHV, NL, SSN, LL, PMK. Reviewed the manuscript: IB,
- 379 EHV, GM, PM, JCT, EDV, EB, YM, AT, CVD, EA, LMM, FMK, SH, NH, EKL, JCMC, AR, JK, NL, PK,
- 380 EBM, JA, OT, RK, KV, TW, CK, DM, SA, JJMT, SSN, LL, PMK. Had full access to the data: IB,
- 381 EHV, AT, SSN, LL, PMK. All authors contributed to review and approved the final version of
- the manuscript.

# 383 **DATA SHARING**

- 384 De-identified participant data collected for the study will be made available from the
- 385 corresponding author upon reasonable request (i.e., when ethically viable without violating
- the protection of participants or other valid ethical, privacy, or security concerns).

It is made available under a CC-BY-NC-ND 4.0 International license .

### 388 **REFERENCES**

- Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, et al.
   Monkeypox. The Lancet. 2023 Jan 7;401(10370):60–74.
- 3912.2022-24 Mpox (Monkeypox) Outbreak: Global Trends [Internet]. [cited 2024392Sep24].Availablefrom:393https://worldhealthorg.shinyapps.io/mpx global/#43 Case profile (overall)
- Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al.
   Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and
   epidemiological report. Lancet Infect Dis. 2019 Aug 1;19(8):872.
- Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.
   Monkeypox Virus Infection in Humans across 16 Countries April-June 2022. N
   Engl J Med. 2022 Aug 25;387(8):679–91.
- Bangwen E, Diavita R, De Vos E, Hasivirwe Vakaniaki E, Nundu SS, Mutombo A,
  et al. Mpox in the Democratic Republic of Congo: Analysis of National
  Epidemiological and Laboratory Surveillance Data, 2010 2023. 2024 [cited
  2024 Oct 23]; Available from: https://papers.ssrn.com/abstract=4954317
- 4046.Kinganda-Lusamaki E, Amuri-Aziza A, Fernandez-Nuñez N, Makangara-Cigolo405JC, Pratt C, Vakaniaki EH, et al. Clade I mpox virus genomic diversity in the406Democratic Republic of the Congo, 2018–2024: Predominance of zoonotic407transmission. Cell. 2024 Oct;0(0).
- Pittman PR, Martin JW, Kingebeni PM, Tamfum JJM, Mwema G, Wan Q, et al.
  Clinical characterization and placental pathology of mpox infection in
  hospitalized patients in the Democratic Republic of the Congo. PLoS Negl Trop
  Dis. 2023 Apr 1;17(4).
- Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, et al.
   Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance
   in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. J
   Infect Dis. 2021 Jun 4;223(11):1870–8.

It is made available under a CC-BY-NC-ND 4.0 International license .

416	9.	McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS,
417		et al. Human Monkeypox in the Kivus, a Conflict Region of the Democratic
418		Republic of the Congo. Am J Trop Med Hyg. 2015 Oct 1;93(4):718–21.
419	10.	Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T,
420		Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I
421		lineage in eastern Democratic Republic of the Congo. Nat Med. 2024;
422	11.	Masirika LM, Udahemuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et
423		al. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with
424		monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the
425		Congo, 2024. Eurosurveillance. 2024 Mar 14;29(11).
426	12.	Nextstrain / groups / inrb-mpox / clade-l [Internet]. [cited 2024 Nov 7].
427		Available from: https://nextstrain.org/groups/inrb-mpox/clade-
428		I?c=date_submitted&f_clade_membership=clade%20Ib&f_division=Sud%20Kiv
429		u
430	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF,
430 431	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing
430 431 432	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic
430 431 432 433	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024
430 431 432 433 434	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835.
430 431 432 433 434 435	13. 14.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of
430 431 432 433 434 435 436	13. 14.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from:
430 431 432 433 434 435 436 437	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares-
430 431 432 433 434 435 436 437 438	13.	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares- mpox-outbreak-a-public-health-emergency-of-international-concern
430 431 432 433 434 435 436 437 438 439	<ul><li>13.</li><li>14.</li><li>15.</li></ul>	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares- mpox-outbreak-a-public-health-emergency-of-international-concern Ministère de la santé publique hygiène et prévention P du SKDP de la santé.
430 431 432 433 434 435 436 437 438 439 440	<ol> <li>13.</li> <li>14.</li> <li>15.</li> </ol>	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares- mpox-outbreak-a-public-health-emergency-of-international-concern Ministère de la santé publique hygiène et prévention P du SKDP de la santé. Pyramide sanitaire des zones de sante 2024. 2024.
430 431 432 433 434 435 436 437 438 439 440 441	<ol> <li>13.</li> <li>14.</li> <li>15.</li> <li>16.</li> </ol>	<ul> <li>Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835.</li> <li>WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares- mpox-outbreak-a-public-health-emergency-of-international-concern</li> <li>Ministère de la santé publique hygiène et prévention P du SKDP de la santé. Pyramide sanitaire des zones de sante 2024. 2024.</li> <li>Damhorst GL, McLendon K, Morales E, Solis ZM, Fitts E, Bowers HB, et al.</li> </ul>
430 431 432 433 434 435 436 437 438 439 440 441 442	<ol> <li>13.</li> <li>14.</li> <li>15.</li> <li>16.</li> </ol>	Murhula Masirika L, Claude Udahemuka J, Schuele L, Nieuwenhuijse DF, Ndishimye P, Boter M, et al. Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv. 2024 Sep 19;2024.09.18.24313835. WHO Director-General declares mpox outbreak a public health emergency of international concern [Internet]. [cited 2024 Sep 24]. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares- mpox-outbreak-a-public-health-emergency-of-international-concern Ministère de la santé publique hygiène et prévention P du SKDP de la santé. Pyramide sanitaire des zones de sante 2024. 2024. Damhorst GL, McLendon K, Morales E, Solis ZM, Fitts E, Bowers HB, et al. Performance of the Xpert <sup>™</sup> Mpox PCR assay with oropharyngeal, anorectal,

It is made available under a CC-BY-NC-ND 4.0 International license .

Català A, Clavo-Escribano P, Riera-Monroig J, Martín-Ezquerra G, Fernandez-Gonzalez
P, Revelles-Peñas L, et al. Monkeypox outbreak in Spain: clinical and epidemiological
findings in a prospective cross-sectional study of 185 cases. British Journal of
Dermatology. 2022 Nov 1;187(5):765–72.

- 448 18. Ježek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical
  449 Features of 282 Patients. J Infect Dis. 1987 Aug 1;156(2):293–8.
- 450 19. Jezek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M. Clinico-epidemiological
  451 features of monkeypox patients with an animal or human source of infection. Bull
  452 World Health Organ. 1988;66(4):459.
- 453 20. Osadebe L, Hughes CM, Shongo Lushima R, Kabamba J, Nguete B, Malekani J, et al.
  454 Enhancing case definitions for surveillance of human monkeypox in the Democratic
  455 Republic of Congo. PLoS Negl Trop Dis. 2017 Sep 11;11(9).
- 456 21. Hoff NA, Morier DS, Kisalu NK, Johnston SC, Doshi RH, Hensley LE, et al. Varicella
  457 Coinfection in Patients with Active Monkeypox in the Democratic Republic of the
  458 Congo. Ecohealth. 2017 Sep 1;14(3):564–74.
- 459 22. Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, et al. A tale of two
  460 viruses: Coinfections of monkeypox and varicella zoster virus in the democratic
  461 republic of congo. American Journal of Tropical Medicine and Hygiene. 2021 Feb
  462 1;104(2):604–11.
- 463 23. Ogoina D, Dalhat MM, Denue BA, Okowa M, Chika-Igwenyi NM, Yusuff HA, et al.
  464 Clinical characteristics and predictors of human mpox outcome during the 2022
  465 outbreak in Nigeria: a cohort study. Lancet Infect Dis. 2023 Dec 1;23(12):1418–28.
- 466 24. Nizigiyimana A, Ndikumwenayo F, Houben S, Manirakiza M, van Lettow M,
  467 Liesenborghs L, et al. Epidemiological analysis of confirmed mpox cases, Burundi, 3
  468 July to 9 September 2024. Euro Surveill. 2024 Oct 17;29(42).
- 469 25. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al.
  470 Maternal and Fetal Outcomes among Pregnant Women with Human Monkeypox

It is made available under a CC-BY-NC-ND 4.0 International license .

471		Infection in the Democratic Republic of Congo. Journal of Infectious Diseases. 2017
472		Nov 1;216(7):824–8.
473	26.	Sanchez Clemente N, Coles C, Paixao ES, Brickley EB, Whittaker E, Alfven T, et al.
474		Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.
475		Lancet Glob Health. 2024 Apr 1;12(4):e572–88.
476	27.	Breman JG, Kalisa-Ruti, Steniowski M V., Zanotto E, Gromyko Al, Arita I. Human
477		monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165.
478	28.	Hutin YJF, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al. Outbreak of
479		Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis.
480		2001 Jun;7(3):434–8.
481		

It is made available under a CC-BY-NC-ND 4.0 International license .

# 483 **TABLES**

	All suspected cases (n = 511)	MPXV positive (n = 431)	MPXV negative (n = 80)	Adjusted p value
Demographics				
Age, years - median (IQR)	22 (14-29)	22 (17-29)	17 (4-31)	0.034
Age group – n (%)				0.005
0-4 years	84/511 (16%)	63/431 (15%)	21/80 (26%)	
5-9 years	24/511 (5%)	18/431 (4%)	6/80 (8%)	
10-14 years	22/511 (4%)	14/431 (3%)	8/80 (10%)	
15-34 years	311/511 (61%)	279/431 (65%)	32/80 (40%)	
35-49 years	58/511 (11%)	52/431 (12%)	6/80 (8%)	
≥ 50 years	12/511 (2%)	5/431 (1%)	7/80 (9%)	
Female– n (%)	241/511 (47%)	205/431 (47%)	36/80 (45%)	0.871
Occupation – n (%)	,		,	0.005
Sex worker	57/498 (11%)	53/419 (13%)	4/79 (5%)	
Mine worker	106/498 (21%)	100/419 (24%)	6/79 (8%)	
Healthcare worker	4/498 (1%)	4/419 (1%)	0/79 (0%)	
Barman	6/498 (1%)	6/419 (1%)	0/79 (0%)	
Teacher	3/498 (1%)	2/419 (1%)	1/79 (1%)	
Student	53/498 (11%)	40/419 (2%)	13/79 (17%)	
Services	87/498 (18%)	70/419 (17%)	8/79 (10%)	
Manual worker	42/498 (8%)	35/419 (8%)	7/79 (9%)	
Unemployed	6/498 (1%)	2/419 (1%)	4/79 (5%)	
Exposure				
Exposure to animal reservoir $f - n$ (%)	63/441 (14%)	58/366 (16%)	5/75 (7%)	0.105
Sex in the previous 3 weeks – n (%)	324/402 (81%)	293/348 (84%)	31/54 (57%)	0.001
# of partners – median (IQR)	1 (1-3)	1 (1-3)	1 (1-1)	0.055
Engaged in transactional sex	143/369 (39%)	135/318 (42%)	8/51 (16%)	0.003
Consistent use of condoms <sup>\$</sup>	13/311 (4%)	12/280 (4%)	1/31 (3%)	1.000
Contact with suspected or confirmed case – n (%)	286/510 (56%)	253/430 (59%)	33/80 (41%)	0.015
median (IQR)	1 (1-2)	1 (1-2)	1 (1-2)	1.000
Multiple or continuous exposure	255/270 (94%)	225/239 (94%)	30/31 (97%)	1.000
Time since last exposure, days – median (IQR) Relation with the contact <sup>#</sup> – n	4 (1-10)	4 (1-10)	1 (1-5)	0.006
(%)				0.020
Family (same household)	144/279 (52%)	121/247 (49%)	23/32 (72%)	
Family (different household)	12/279 (4%)	7/247 (3%)	5/32 (16%)	
Neighbor	19/279 (7%)	17/247 (7%)	2/32 (6%)	
Colleague	88/279 (32%)	81/247 (33%)	7/32 (22%)	
Sexual	50/279 (18%)	50/247 (20%)	0/32 (0%)	
Sexual partner	11/279 (4%)	11/247 (5%)	0/32 (0%)	
Client of sex worker	17/279 (6%)	17/247 (7%)	0/32 (0%)	
Sex worker	21/279 (8%)	21/247 (9%)	0/32 (0%)	
Patient of the participant	2/279 (1%)	2/247 (1%)	0/32 (0%)	

#### It is made available under a CC-BY-NC-ND 4.0 International license .

Other	5/279 (2%)	5/247 (2%)	0/32 (0%)	
Type of exposure§ – n (%)				
Prolonged (> 15 min) discussion	274/286 (96%)	243/253 (96%)	31/33 (94%)	0.809
Direct skin to skin contact	279/286 (98%)	246/253 (97%)	33/33 (100%)	1.000
Sexual contact	114/286 (40%)	107/253 (42%)	7/33 (21%)	0.058
Care giving Sharing meals and/or eating	67/286 (23%)	57/253 (23%)	10/33 (30%)	0.562
utensils	254/286 (89%)	227/253 (90%)	27/33 (82%)	0.363
Sharing bed and/or bedlinen	197/286 (69%)	176/253 (70%)	21/33 (64%)	0.733
Sharing clothes	36/286 (13%)	29/253 (12%)	7/33 (21%)	0.258

Data are median and IQR for numeric variables and n/N (%) for categorical variables. N signifies the number of included individuals with available data. <sup>£</sup>Exposure to animal reservoir is defined as involvement in activities such as hunting, capturing, or consuming rodents, eating bushmeat, or handling or consuming animals found dead. <sup>§</sup>Consistent use of condoms means the use of condoms for (nearly) all sexual contact. <sup>#</sup>Spouses were reported as family members. The sum exceeds 100% because the relationship is defined per index case, 1 participant can have > 1 index case. <sup>§</sup>Multiple answers per participant are possible, the numerator indicates the number of participants that had the specific exposure type with at least one index case.

Abbreviations: IQR = interquartile range, min = minutes, MPXV = monkeypox virus

*Table 1:* Demographic profile and exposure risk of suspect mpox cases in Kamituga, DRC, by infection status

485

486

It is made available under a CC-BY-NC-ND 4.0 International license .

	All confirmed	Per age category (years)		vears)
	cases (n = 431)	0-4	5-14	≥15
	(	(n = 63)	(n = 32)	(n = 336)
Medical history				
Childhood smallpox vaccination – n (% )	7/308 (2%)			7/308 (2%)
Previous mpox* – n (%)	2/420 (1%)	0/62 (0%)	0/32 (0%)	2/326 (1%)
Comorbidities – n (%)	18/422 (4%)	0/61 (0%)	2/32 (6%)	16/329 (5%)
HIV	6/422 (1%)	0/61 (0%)	1/32 (3%)	5/329 (2%)
Under ART	3/6 (60%)		1/1 (100%)	2/4 (50%)
Tuberculosis	5/431 (1%)	0/63 (0%)	1/32 (3%)	4/336 (1%)
Diabetes	1/431 (0%)	0/63 (0%)	0/32 (0%)	1/336 (0%)
Chronic liver disease	1/431 (0%)	0/63 (0%)	1/32 (3.1)	0/336 (0%)
Chronic pulmonary disease	3/431 (1%)	0/63 (0%)	0/32 (0%)	3/336 (1%)
Rheumatic disease	1/431 (0%)	0/63 (0%)	0/32 (0%)	1/336 (0%)
Arterial hypertension	2/431 (1%)	0/63 (0%)	0/32 (0%)	2/336 (1%)
Malnutrition# – n (%)	10/375 (3%)	5/56 (9%)	3/28 (11%)	2/291 (1%)
Moderate malnutrition	9/375 (2%)	4/56 (7%)	3/28 (11%)	2/291 (1%)
Severe malnutrition	1/375 (0%)	1/56 (2%)	0/28 (0%)	0/291 (0%)
Pregnancy – n (%)	21/205 (10%)	0 (0%)	0 (0%)	21/161 (13%)
1st trimester	5/20 (25%)			5/20 (25%)
2nd trimester	10/20 (50%)			10/20 (50%)
3rd trimester	5 /20 (25%)			5/20 (25%)
Clinical presentation				
Symptoms onset, days – median (IQR)				
Any symptom	7 (5-10)	6 (3-8)	5 (4-7)	8 (6-10)
Lesions	5 (4-7)	4 (3-6)	3 (3-4)	5 (4-7)
Prodromal phase <sup>±</sup> – n (%)	346/395 (88%)	40/52 (77%)	23/29 (79%)	283/314 (90%)
Symptoms – n (%)				
Fatigue	384/429 (90%)	53/62 (86%)	28/32 (88%)	303/335 (90%)
Malaise	320/428 (75%)	34/61 (56%)	26/32 (81%)	260/335 (78%)
Myalgia	301/423 (71%)	31/57 (54%)	21/31 (68%)	249/335 (74%)
Pain associated with lesions	333/426 (78%)	40/59 (68%)	26/32 (81%)	267/335 (80%)
Itching	390/426 (92%)	52/59 (88%)	31/32 (97%)	307/335 (92%)
Cough	150/427 (35%)	30/61 (49%)	9/32 (28%)	111/334 (33%)
Shortness of breath	59/428 (14%)	12/61 (20%)	0/32 (0%)	47/335 (14%)
Anorexia	244/429 (57%)	22/62 (36%)	22/32 (69%)	200/335 (60%)
Throat ache / dysphagia	233/426 (55%)	11/59 (19%)	23/32 (72%)	199/335 (59%)
Abdominal pain	128/424 (30%)	7/58 (12%)	10/32 (31%)	111/334 (33%)
Nausea / vomiting	97/428 (23%)	7/61 (12%)	9/32 (28%)	81/335 (24%)
Diarrhea	54/428 (13%)	7/61 (12%)	3/32 (9%)	44/335 (13%)
Headache	249/422 (59%)	2/56 (4%)	18/32 (56%)	229/334 (69%)
Confusion	12/428 (3%)	1/61 (2%)	2/32 (6%)	9/335 (3%)
Convulsions	1/429 (0%)	1/62 (2%)	0/32 (0%)	0/335 (0%)
Eye pain	85/426 (20%)	0/60 (0%)	4/32 (13%)	81/334 (24%)

42/426 (10%)

46/424 (11%)

168/425 (40%)

22/428 (5%)

117/229 (51%)

21/424 (5%)

59/416 (14%)

110/365 (30%)

5/397 (1%)

9/417 (2%)

18/400 (5%)

417/428 (97%)

414/431 (96%)

141/414 (34%)

89/413 (22%)

37/414 (9%)

...

298/431 (78%)

228/431 (61%)

241/431 (62%)

270/431 (71%)

329/431 (83%)

167/431 (42%)

288/431 (74%)

100/431 (20%)

328/431 (61%)

136/431 (29%)

62/414 (15%)

222/414 (54%)

291/414 (70%)

178/414 (43%)

156/414 (38%)

94/414 (23%)

162/414 (39%)

51/414 (12%)

88/414 (21%)

98/411 (24%)

42 (17-94)

338/414 (82%)

102/412 (25%)

187/410 (46%)

149/215 (69%)

Visual problems

Rectal pain

Dysuria

Vital signs - n (%)

94%

Skin lesions – n (%)

Active lesions<sup>£</sup>

Rash pattern

Hematuria

Genital pain

Tachycardia<sup>1</sup>

Tachypnea<sup>µ</sup>

MAP < 60 mmHg

Oxygen saturation <

Capillary refill > 2 sec

Generalized<sup>€</sup>

Predominantly

Head and neck

Palms of the hands

Soles of the feet

genital<sup>\$</sup> Only genital

Lesion distribution

Chest

Back

Arms

Legs

Genital

Macule

Papule

Vesicle

Ulcer

Crust

Scar

Monomorphic<sup>§</sup>

Complex lesions<sup>a</sup>

Total lesion count - median

Mucosal lesions - n (%)

Oral

Tonsillar

Penile

(IQR)

25

Small pustule

Umbilicated pustule

Anal

Туре

Abdomen

Temperature > 38 °C

It is made available under a CC-BY-NC-ND 4.0 International license .

0/60 (0%)

1/59 (2%)

1/58 (2%)

1/61 (2%)

1/58 (2%)

4/62 (7%)

5/56 (9%)

23/54 (43%)

2/35 (6%)

2/61 (3%)

3/59 (5%)

59/62 (95%)

58/63 (92%)

14/58 (24%)

1/58 (2%)

1/58 (2%)

...

48/63 (83%)

31/63 (53%)

36/63 (62%)

46/63 (79%)

48/63 (83%)

19/63 (33%)

43/63 (74%)

11/63 (19%)

17/63 (29%)

14/63 (25%)

...

15/58 (26%)

42/58 (72%)

27/58 (47%)

23/58 (40%)

6/58 (10%)

2/58 (3%)

15/58 (26%)

5/58 (9%)

22/58 (38%)

1/58 (2%)

50 (30-108)

25/58 (43%)

11/58 (19%)

13/57 (23%)

9/31 (29%)

0/31 (0%)

0/31 (0%)

1/32 (3%)

0/32 (0%)

0/32 (0%)

2/32 (6%)

13/31 (42%)

12/25 (48%)

2/31 (7%)

1/32 (3%)

3/28 (11%)

32/32

(100%)

32/32

(100%)

11/32 (34%)

1/32 (3%)

0/32 (0%)

...

26/32 (81%)

24/32 (75%)

22/32 (69%)

23/32 (72%)

28/32 (88%)

17/32 (53%)

26/32 (81%)

5/32 (16%)

20/32 (63%)

9/32 (28%)

••

4/32 (13%)

24/32 (75%)

15/32 (47%)

11/32 (34%)

8/32 (25%)

3/32 (9%)

5/32 (16%)

2/32 (6%)

14/32 (44%)

3/32 (9%) 103 (27-

186)

26/32 (81%)

12/32 (38%)

19/32 (59%)

6/16 (38%)

42/335 (13%)

45/334 (14%)

166/335 (50%)

21/335 (6%)

116/221 (53%)

15/330 (5%)

41/329 (13%)

75/286 (26%)

1/331 (0%)

6/324 (2%)

12/313 (4%)

326/334 (98%)

324/336 (96%)

116/324 (36%)

87/323 (27%)

36/324 (11%)

...

224/336 (69%)

173/336 (53%)

183/336 (57%)

201/336 (62%)

253/336 (78%)

131/336 (40%)

219/336 (68%)

84/336 (26%)

291/336 (90%)

113/336 (35%)

43/324 (13%

156/324 (48%)

249/324 (77%)

144/324 (44%)

142/324 (44%)

89/324 (28%)

142/324 (44%)

44/324 (14%)

52/324 (16%)

94/321 (29%)

38 (16-83)

287/324 (89%)

79/322 (25%)

155/321 (48%)

134/168 (80%)

It is made available under a CC-BY-NC-ND 4.0 International license .

Vaginal	144/195 (74%)	6/26 (23%)	8/15 (53%)	130/154 (84%)	
Lymphadenopathy – n (%)	295/414 (71%)	9/58 (16%)	22/32 (69%)	264/324 (82%)	
Retro-auricular	48/414 (12%)	5/58 (9%)	8/32 (25%)	35/324 (11%)	
Submandibular	90/414 (22%)	8/58 (14%)	15/32 (47%)	67/324 (21%)	
Cervical	27/414 (7%)	1/58 (2%)	2/32 (6%)	24/324 (7%)	
Supra clavicular	2/414 (1%)	0/58 (0%)	0/32 (0%)	2/324 (1%)	
Axillar	23/414 (6%)	0/58 (0%)	1/32 (3%)	22/324 (7%)	
Inguinal	260/414 (63%)	4/58 (7%)	10/32 (31%)	246/324 (76%)	

Data are median and IQR for numeric variables and n/N (%) for categorical variables. N signifies the number of individuals with available data. \*Previous mpox refers to suspected or confirmed MPXV infection, diagnosed at least 4 weeks prior to presentation. ±Prodromal phase refers to onset of other symptoms prior to onset of lesions. #Nutritional status is evaluated by age: severe malnutrition is defined as MUAC < 11.5 cm for children under 5 years old, BMI for age below -3 SD for children 5 to 19 years old and as BMI below 16 kg/m<sup>2</sup> for adults over 19 years old, moderate malnutrition is defined as MUAC 11.5 to 12.5 cm for children under 5 years old, BMI for age -2 to -3 SD for children 5 to 19 years old and as BMI 16 to 18 kg/m<sup>2</sup> for adults over 19 years old ¶Tachycardia is defined in relation to age: > 190 bpm for newborns 0 to 1 month, > 160 bpm for infants 1 to 11 months, > 140 bpm for 1 to 2 years, > 120 bpm for 3 to 7 years, > 100 bpm for older children, teens and adults. µTachypnea is defined in relation to age: > 40 brpm for newborns and infants 0 to 1 year, > 30 brpm for 1 to 7 years, > 25 brpm for older children to 12 years, > 20 brpm for teens and adults. £Active lesions are skin lesions that have not evolved to a crust or scar. €Generalized rash are skin lesions that are present on at least 8 out of ten body regions: head and neck, chest, abdomen, back, arms, palms of the hands, legs, soles of the feet, genital or anal. \$Predominantly genital rash means that the number of skin lesions on the genitals represent > 50% of the total lesion count. §Monomorphic refers to skin lesions of the same size and appearance. LComplex lesions refers to lesions that are confluent, greater than 2 cm along the largest diameter and/or necrotizing.

Abbreviations: ART = antiretroviral therapy, BMI = body mass index, bpm = beats per minute, brpm = breaths per minute, HIV = human immunodeficiency virus, IQR = interquartile range, MAP = mean arterial pressure, MPXV = monkeypox virus, MUAC = mid upper arm circumference, SD = standard deviation, WHO = world health organization

*Table 2:* Medical history and clinical presentation of confirmed mpox cases in Kamituga, DRC (2024) in relation to age categories

489

490

#### It is made available under a CC-BY-NC-ND 4.0 International license .

492

	All confirmed cases (n=315)	irmed Per age category (years)		vears)
	,	0-4 (n=39)	5-14 (n=19)	≥15 (n=257)
Duration of hospitalization – median	6 (5-9)	5 (4-7)	4.5 (4-5)	7 (5-9)
Maximum lesion count – median (IQR)	59 (23-139)	54 (14-227)	100 (48- 167)	58 (23-121)
WHO severity score – n (%)				
Mild (< 25 lesions)	78/311 (25%)	12/38 (32%)	3/19 (16%)	63/254 (25%)
Moderate (25-99 lesions)	126/311 (41%)	10/38 (26%)	6/19 (32%)	110/254 (43%)
Severe (100-250 lesions)	60/311 (19%)	8/38 (21%)	9/19 (47%)	43/254 (17%)
Grave (> 250 lesions)	47/311 (15%)	8/38 (21%)	1/19 (5%)	38/254 (15%)
Any Complications – n (%)	( )		- ()	185/257
	200/315 (64%)	9/39 (23%)	6/19 (32%)	(72%)
Cutaneous Complications – n (%)	125/315 (40%)	4/39 (10%)	6/19 (32%)	115/257 (45%)
Superinfection – n (%)	57/315 (18%)	3/39 (8%)	3/19 (16%)	51/257 (20%)
Abscess – n (%)	21/315 (7%)	1/39 (3%)	1/19 (5%)	19/257 (7%)
Complex lesion <sup>□</sup> − n (%)	102 (32%)	2 (5%)	3 (16%)	97 (38%)
Lymph node abscess– n (%)	6/315 (2%)	0/39 (0%)	0/19 (0%)	6/257 (2%)
Genito-urinary complications – n (%)	172/215 (550/)	1/20 (20/)	1/10 (59/)	171/257
Complex lesions of genital	173/315 (55%)	1/39 (3%)	1/19 (5%)	(07%)
mucosa	120/315 (38%)	0/39 (0%)	1/19 (5%)	119/257 (46%)
Urinary retention	24/315 (8%)	1/39 (3%)	0/19 (0%)	23/257 (9%)
Urethritis			_ / /	120/257
Conital adama	121/315 (38%)	1/39 (3%)	0/19 (0%)	(47%)
Baranhimosia	121/315 (38%)	1/39 (3%)	1/19 (5%)	119/257 (46%)
	2/315 (1%)	0/39 (0%)	0/19 (0%)	2/257 (1%)
Proclius Cordia pulmonory complications on (0()	15/315 (5%)	0/39 (0%)	0/19 (0%)	15/257 (6%)
Cardio-pulmonary complications – n (%)	13/315 (4%)	7/39 (18%)	0/19 (0%)	6/257 (2%)
	3/315 (1%)	2/39 (5%)	0/19 (0%)	1/257 (0%)
	11/315 (4%)	7/39 (18%)	0/19 (0%)	4/257 (2%)
Hypervolemia	1/315 (0%)	0/39 (0%)	0/19 (0%)	1/257 (0%)
Respiratory distress	2/315 (1%)	2/39 (5%)	0/19 (0%)	0/257 (0%)
Neuro-ophthalmic complications – n (%)	9/315 (3%)	2/39 (5%)	0/19 (0%)	7/257 (3%)
Meningitis or encephalitis	2/315 (1%)	2/39 (5%)	0/19 (0%)	0/257 (0%)
Conjunctivitis or uveitis	8/315 (3%)	1/39 (3%)	0/19 (0%)	7/257 (3%)
Vision loss or reduced	0/315 (0%)	0/39 (0%)	0/19 (0%)	0/257 (0%)
Metabolic <sup>#</sup> complications – n (%)	0/315 (0%)	0/39 (0%)	0/19 (0%)	0/257 (0%)

Data are median and |QR| for numeric variables and n/N (%) for categorical variables. N signifies the number of individuals with available data.  $\Box$  Complex lesions refers to lesions that are confluent, greater than 2 cm along the largest diameter and/or necrotizing. #Registered metabolic complications include hypoglycemia and icterus.

*Table 3.* Complications at any timepoint during hospitalization for mpox treatment in Kamituga, DRC (2024)

493

494

It is made available under a CC-BY-NC-ND 4.0 International license .

### 496 Table 4

	Day 29 (n =208)	Day 59 (n = 102)
Deterioration of general health since mpox – n (%)	2/206 (1%)	0/102 (0%)
Medical care for ongoing health issues – n (%)	11/81 (14%)	3/38 (8%)
Persistent symptoms		
Any – n (%)	78/208 (38%)	38/103 (37%)
Constitutional – n (%)	20/208 (10%)	9/103 (9%)
Fatigue	9/207 (4%)	4/103 (4%)
Malaise	5/207 (2%)	0/103 (0%)
Myalgia	6/207 (3%)	0/103 (0%)
Headache	11/206 (5%)	5/100 (5%)
Anorexia	2/208 (1%)	2/102 (2%)
Skin – n (%)	40/208 (19%)	15/102 (15%)
Pain associated with lesions	5/208 (2%)	0/102 (0%)
Itching	36/207 (17%)	15/101 (15%)
Psychiatric – n (%)	13/208 (6%)	6/103 (6%)
Depression	1/208 (1%)	0/103 (0%)
Anxiety	13/208 (6%)	6/102 (6%)
Respiratory – n (%)	9/208 (4%)	6/103 (6%)
Cough	7/208 (3%)	6/103 (6%)
Shortness of breath	2/208 (1%)	0/103 (0%)
Gastro-intestinal – n (%)	11/208 (5%)	2/103 (2%)
Throat ache / dysphagia	5/208 (2%)	0/102 (0%)
Abdominal pain	5/206 (2%)	1/101 (1%)
Nausea / vomiting	2/208 (1%)	1/103 (1%)
Diarrhea	3/208 (1%)	0/103 (0%)
Rectal pain	1/208 (1%)	0/103 (0%)
Pain on defecation	2/207 (1%)	0/103 (0%)
Genito-urinary – n (%)	15/208 (7%)	4/103 (4%)
Dysuria	5/208 (2%)	0/103 (0%)
Genital pain	3/172 (2%)	1/87 (1%)
Dyspareunia	4/159 (3%)	2/86 (2%)
Vaginal discharge	4/84 (5%)	2/41 (5%)
Vaginal dryness	6/82 (7%)	4/41 (10%)
Adhesions of the foreskin	1/107 (1%)	0/52 (0%)
Painful erection	2/87 (2%)	0/45 (0%)
Eye – n (%)	22/207 (11%)	18/102 (18%)
Eye pain	9/204 (4%)	4/101 (4%)
Photophobia	14/203 (7%)	11/100 (11%)
Itching	15/206 (7%)	12/102 (12%)
Foreign body sensation	8/203 (4%)	9/99 (9%)
Reduced visual acuity	5/206 (2%)	5/101 (5%)
Blindness	0/207 (0%)	1/101 (1%)
Persistent lesions		
Active skin lesions – n (%)	5/206 (2%)	1/103 (1%)
Scars – n (%)	153/208 (74%)	51/103 (50%)
Eye – n (%)	9/208 (4%)	2/103 (2%)
Eye lid edema	1/207 (1%)	1/102 (1%)

It is made available under a CC-BY-NC-ND 4.0 International license .

8/207 (4%)	2/102 (2%)
	( )
1/207 (1%)	2/102 (2%)
1/207 (1%)	1/102 (1%)
	1/207 (1%) 1/207 (1%)

Table 4. Clinical sequelae at day 29	and day 59 after mpox diagnosis	in Kamituga, DRC (2024)
--------------------------------------	---------------------------------	-------------------------

It is made available under a CC-BY-NC-ND 4.0 International license .

# 501 FIGURES LEGENDS

502

503 Figure 1. Demographics, Clinical Presentation and Evolution of Clade Ib mpox, South-Kivu, 504 **DRC** (A) Age and sex distribution of confirmed mpox participants. (B) Body map indicating 505 the proportion of participants with lesions in a given body region at inclusion for adults (>= 506 15 years) and children 0-14 years. (C) Body map indicating density of skin lesions per body 507 region for individuals of 15 years old and above, and children aged 0 to 14 years old , 508 expressed as mean number of lesions (n) per percentage of total body surface area (TBSA) 509 according to a modified Lund-Browder chart for estimated TBSA. (D) Body map indicating 510 the proportion of participants with scars in a given body region on day 59 after diagnosis 511 for adults (>= 15 years) and children 0-14 years. (E) Kaplan-Meier estimates for time from onset of active lesions to resolution, with 95% confidence interval. (F) Kaplan-Meier 512 513 estimates for time from onset of symptoms to resolution of all symptoms, with 95% 514 confidence Interval.

515

Figure 2. Clinical images of skin and genital mpox lesions (A) Papular, umbilicated and ulcerated lesions on the hand. (B)Complex skin and genital mucosal lesion with labial edema, surrounded by papules and umbilicated genital skin lesions in adult female. (C) Complex genital skin lesion in adult female. (D) Umbilicated lesions with high lesion density on the head and neck. (E) Genital mpox complicated with Fourniers gangrene in an adult male. (F) Ulcerated and necrotic lesions on the penis and upper thigh in adult male.





presence of lesions % of participants

presence of scars % of participants

Ε



F









B



